Andrew Catchpole

1.3k total citations
21 papers, 329 citations indexed

About

Andrew Catchpole is a scholar working on Epidemiology, Infectious Diseases and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Andrew Catchpole has authored 21 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 8 papers in Infectious Diseases and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Andrew Catchpole's work include Respiratory viral infections research (12 papers), Influenza Virus Research Studies (6 papers) and Viral gastroenteritis research and epidemiology (4 papers). Andrew Catchpole is often cited by papers focused on Respiratory viral infections research (12 papers), Influenza Virus Research Studies (6 papers) and Viral gastroenteritis research and epidemiology (4 papers). Andrew Catchpole collaborates with scholars based in United Kingdom, United States and Netherlands. Andrew Catchpole's co-authors include Rob Lambkin‐Williams, Anthony Gilbert, Alex Mann, Nicolas Noulin, Christopher Chiu, John Oxford, Alex Mann, Shobana Balasingam, Garth Rapeport and Daniel A. Scott and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Journal of General Virology.

In The Last Decade

Andrew Catchpole

20 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Catchpole United Kingdom 10 180 141 76 42 35 21 329
Athanasios Kossyvakis Greece 12 198 1.1× 186 1.3× 34 0.4× 26 0.6× 44 1.3× 26 404
Gabriela Abelenda-Alonso Spain 9 126 0.7× 169 1.2× 20 0.3× 23 0.5× 34 1.0× 26 304
Zach Stednick United States 9 174 1.0× 137 1.0× 63 0.8× 16 0.4× 36 1.0× 15 313
Mauricio T. Caballero Argentina 12 298 1.7× 164 1.2× 158 2.1× 48 1.1× 47 1.3× 24 464
TM Uyeki United States 2 274 1.5× 99 0.7× 46 0.6× 27 0.6× 11 0.3× 3 317
Michael D. Nowak United States 7 133 0.7× 244 1.7× 28 0.4× 14 0.3× 28 0.8× 21 363
Daixi Jiang China 14 282 1.6× 243 1.7× 29 0.4× 30 0.7× 37 1.1× 31 523
Lianhe Lu China 3 407 2.3× 215 1.5× 32 0.4× 54 1.3× 23 0.7× 8 499
Patricio L. Acosta Argentina 10 248 1.4× 170 1.2× 133 1.8× 59 1.4× 36 1.0× 21 422
Eloise Wells Switzerland 2 248 1.4× 88 0.6× 44 0.6× 23 0.5× 76 2.2× 3 363

Countries citing papers authored by Andrew Catchpole

Since Specialization
Citations

This map shows the geographic impact of Andrew Catchpole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Catchpole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Catchpole more than expected).

Fields of papers citing papers by Andrew Catchpole

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Catchpole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Catchpole. The network helps show where Andrew Catchpole may publish in the future.

Co-authorship network of co-authors of Andrew Catchpole

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Catchpole. A scholar is included among the top collaborators of Andrew Catchpole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Catchpole. Andrew Catchpole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lindert, Kelly, Alex Mann, Anita Geevarughese, et al.. (2025). Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine. NEJM Evidence. 4(12). EVIDoa2500087–EVIDoa2500087. 1 indexed citations
2.
3.
4.
Trender, William, Peter J. Hellyer, Ben Killingley, et al.. (2024). Changes in memory and cognition during the SARS-CoV-2 human challenge study. EClinicalMedicine. 76. 102842–102842. 9 indexed citations
5.
Phuah, Jia Yao, Brian M. Maas, Aimin Tang, et al.. (2023). Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomedicine & Pharmacotherapy. 169. 115851–115851. 22 indexed citations
6.
Zhou, Jie, Anika Singanayagam, Niluka Goonawardane, et al.. (2023). Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. The Lancet Microbe. 4(8). e579–e590. 35 indexed citations
7.
Smith, Emma, Diane Gbesemete, Halle Johnson, et al.. (2022). The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic. Epidemics. 41. 100626–100626. 1 indexed citations
8.
Schmöele-Thoma, Beate, Agnieszka Zareba, Qin Jiang, et al.. (2022). Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 386(25). 2377–2386. 79 indexed citations
9.
Zhou, Jie, Anika Singanayagam, Niluka Goonawardane, et al.. (2022). Viral Emissions into the Air and Environment after SARS-CoV-2 Human Challenge: A Phase 1, Open Label, First-in-Human Study. SSRN Electronic Journal. 2 indexed citations
10.
Rapeport, Garth, Emma Smith, Anthony Gilbert, et al.. (2021). SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic. New England Journal of Medicine. 385(11). 961–964. 31 indexed citations
11.
12.
Lambkin‐Williams, Rob, Nicolas Noulin, Alex Mann, Andrew Catchpole, & Anthony Gilbert. (2018). The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respiratory Research. 19(1). 123–123. 43 indexed citations
13.
Catchpole, Andrew, et al.. (2018). The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process. BMC Research Notes. 11(1). 620–620. 6 indexed citations
14.
Mori, Julie, Andrew Catchpole, Edward J. Murray, et al.. (2016). A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model. PLoS ONE. 11(12). e0166113–e0166113. 5 indexed citations
15.
Noulin, Nicolas, Andrew Catchpole, Hosnieh Fathi, et al.. (2016). Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS ONE. 11(1). e0145902–e0145902. 9 indexed citations
16.
Laxton, Carl, Andrew Catchpole, E. Donnall Thomas, et al.. (2015). Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM). Journal of Virological Methods. 224. 83–90. 6 indexed citations
17.
Mann, Alex, Nicolas Noulin, Andrew Catchpole, et al.. (2014). Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge. PLoS ONE. 9(5). e93761–e93761. 27 indexed citations
18.
Oxford, John, et al.. (2005). A Throat Lozenge Containing Amyl Meta Cresol and Dichlorobenzyl Alcohol Has a Direct Virucidal Effect on Respiratory Syncytial Virus, Influenza a and SARS-CoV. Antiviral chemistry & chemotherapy. 16(2). 129–134. 27 indexed citations
19.
Oxford, John, et al.. (2005). New Antiviral Drugs, Vaccines and Classic Public Health Interventions against SARS Coronavirus. Antiviral chemistry & chemotherapy. 16(1). 13–21. 9 indexed citations
20.
Catchpole, Andrew, et al.. (1978). Torsional Vibrations of a Vehicle Drive Line. Journal of Mechanical Design. 100(4). 644–650. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Athanasios Kossyvakis Breakdown of academic impact, for papers by Gabriela Abelenda-Alonso Breakdown of academic impact, for papers by Zach Stednick Breakdown of academic impact, for papers by Mauricio T. Caballero Breakdown of academic impact, for papers by TM Uyeki Breakdown of academic impact, for papers by Michael D. Nowak Breakdown of academic impact, for papers by Daixi Jiang Breakdown of academic impact, for papers by Lianhe Lu Breakdown of academic impact, for papers by Patricio L. Acosta Breakdown of academic impact, for papers by Eloise Wells
Rankless by CCL
2026